Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Journey Medical (DERM) Deferred Taxes (2020 - 2021)

Journey Medical filings provide 2 years of Deferred Taxes readings, the most recent being $8.3 million for Q4 2021.

On a quarterly basis, Deferred Taxes rose 2281.27% to $8.3 million in Q4 2021 year-over-year; TTM through Dec 2021 was $1.6 million, a N/A change, with the full-year FY2021 number at $1.6 million, up 567.46% from a year prior.
Deferred Taxes hit $8.3 million in Q4 2021 for Journey Medical, up from -$3.3 million in the prior quarter.
In the past five years, Deferred Taxes ranged from a high of $8.3 million in Q4 2021 to a low of -$3.5 million in Q2 2021.